World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 28 April 2013
Main ID:  NTR875
Date of registration: 19/01/2007
Primary sponsor: VU University Medical Center, Department of Intensive Care
Public title: The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal hemorrhage admitted in the intensive care.
Scientific title: The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal hemorrhage admitted in the intensive care. - Nimodipine subarachnoidal hemorrhage ICU
Date of first enrolment: 1/12/2006
Target sample size: 12
Recruitment status: complete
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=875
Study type:  intervention
Study design:  Randomised: No; Masking: None; Control: Not applicable; Group: [default]; Type: Single arm  
Countries of recruitment
The Netherlands
Contacts
Name: B.M.   Kors
Address:  VU medisch centrum Afdeling intensive care volwassenen Boelelaan 1117 1081 HV Amsterdam The Netherlands
Telephone: + 31 20 4443900
Email: bm.kors@vumc.nl
Affiliation: 
Name: A.R.J  Girbes
Address:  VU medisch centrum afdeling intensive care volwassenen, Boelelaan 1117 1081 HV Alkmaar The Netherlands
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. All patients admitted on the ICU with subarachnoidal hemorrhage (SAB), treated according to our SAB-protocol;

2. Adults aged 18 - 70 years old.

Exclusion criteria: 1. Pregnancy;

2. Expected mortality < 24 hours;

3. Severe hepatic function disorders;

4. Use of medication with know interaction in relation to nimodipine.


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Subarachnoid hemorrhage (SAH), Intensive care

Intervention(s)
Bloodsamples according to strict time protocol during treatment.
Primary Outcome(s)
1. Pharmacokinetics of nimodipine in this specific group of patients;

2. Variability of bio-availability of orally administred nimodipine.
Secondary Outcome(s)
Secondary ID(s)
ISRCTN45381163
N/A
Source(s) of Monetary Support
VU University Medical Center, Department of Intensive Care
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history